Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2018

Open Access 01-12-2018 | Research

Pancreatic fat deposition is increased and related to beta-cell function in women with familial partial lipodystrophy

Authors: Amelio F. Godoy-Matos, Cynthia M. Valerio, Rodrigo O. Moreira, Denise P. Momesso, Leonardo K. Bittencourt

Published in: Diabetology & Metabolic Syndrome | Issue 1/2018

Login to get access

Abstract

Background

To study pancreatic fat deposition and beta-cell function in familial partial lipodystrophy (FPLD) patients.

Methods

In a cross-sectional study, eleven patients with FPLD, and eight healthy volunteers were matched for age and body mass index and studied at a referral center. Body composition was assessed using dual-energy X-ray absorptiometry and the Dixon method of magnetic resonance imaging was used to quantify pancreatic and liver fat. Fasting plasma glucose, insulin, leptin, lipids and homeostasis model assessment of insulin resistance values were measured, and an oral glucose tolerance test was performed. The insulinogenic index, Matsuda insulin sensitivity index and beta-cell disposition index were calculated.

Results

The FPLD group presented a higher waist-to-hip ratio and fat mass ratio and lower total, truncal and lower-limb fat masses. Pancreatic and liver fat contents (log transformed) were significantly higher in the FPLD group (5.26 ± 1.5 vs. 4.08 ± 0.64, p = 0.034 and 0.77 ± 0.50 vs. 0.41 ± 0.18, p = 0.056, respectively). Pancreatic fat was inversely related to the DI (r = − 0.53, p = 0.027) and HDL-cholesterol (r = − 0.63, p = 0.003) and directly related to WHR (r = 0.60; p = 0.009), HbA1c (r = 0.58; p = 0.01) and serum triglyceride (r = 0.48, p = 0.034). Higher triglyceride and lower HDL-cholesterol levels were observed in the FPLD group.

Conclusions

This study demonstrated for the first time that pancreatic fat deposition is increased in FPLD. Moreover, an inverse relationship was demonstrated between pancreatic fat and beta-cell function. The findings of this study may be consistent with the expandability hypothesis and the twin cycle hypothesis.
Literature
1.
go back to reference Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313–25.CrossRef Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313–25.CrossRef
2.
go back to reference Garg A, Peshock R, Fleckenstein J. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 1999;84:170–4.PubMed Garg A, Peshock R, Fleckenstein J. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 1999;84:170–4.PubMed
3.
go back to reference Capeau J, Magré J, Lascols O, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans. 2005;33:1073–7.CrossRef Capeau J, Magré J, Lascols O, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans. 2005;33:1073–7.CrossRef
4.
go back to reference Brown RJ, Committee Chair, Araujo-Vilar D, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101:4500–11.CrossRef Brown RJ, Committee Chair, Araujo-Vilar D, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101:4500–11.CrossRef
5.
go back to reference Valerio CM, Zajdenverg L, Oliveira JEP, Mory PB, Moyses RS, Godoy-Matos AF. Body composition study by dual-energy X-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation. Diabetol Metab Syndr. 2015;7:19.CrossRef Valerio CM, Zajdenverg L, Oliveira JEP, Mory PB, Moyses RS, Godoy-Matos AF. Body composition study by dual-energy X-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation. Diabetol Metab Syndr. 2015;7:19.CrossRef
6.
go back to reference Godoy-Matos AF, Moreira RO, Valerio CM, Mory PB, Moises RS. A new method for body fat evaluation, body adiposity index, is useful in women with familial partial lipodystrophy. Obesity. 2012;20:440–3.CrossRef Godoy-Matos AF, Moreira RO, Valerio CM, Mory PB, Moises RS. A new method for body fat evaluation, body adiposity index, is useful in women with familial partial lipodystrophy. Obesity. 2012;20:440–3.CrossRef
7.
go back to reference Mory PB, Crispim F, Freire MB, Salles JE, Valério CM, Godoy-Matos AF, Dib SA, Moisés RS. Phenotipic diversity in patients with lipodystrophy associated with LMNA mutations. Eur J Endocrinol. 2012;167:423–31.CrossRef Mory PB, Crispim F, Freire MB, Salles JE, Valério CM, Godoy-Matos AF, Dib SA, Moisés RS. Phenotipic diversity in patients with lipodystrophy associated with LMNA mutations. Eur J Endocrinol. 2012;167:423–31.CrossRef
8.
go back to reference Godoy-Matos AF, Valério CM, Bragança JB, Oliveira Rde A, Zagury RL, de Paula Lustosa R, Camargo GC, Nascimento CA, Moreira RO. Evaluation of epicardial adipose tissue in familial partial lipodystrophy. Diabetol Metab Syndr. 2015;7:29.CrossRef Godoy-Matos AF, Valério CM, Bragança JB, Oliveira Rde A, Zagury RL, de Paula Lustosa R, Camargo GC, Nascimento CA, Moreira RO. Evaluation of epicardial adipose tissue in familial partial lipodystrophy. Diabetol Metab Syndr. 2015;7:29.CrossRef
9.
go back to reference Savage DB. Mouse models of inherited lipodystrophy. Dis Model Mech. 2009;2:554–62.CrossRef Savage DB. Mouse models of inherited lipodystrophy. Dis Model Mech. 2009;2:554–62.CrossRef
10.
go back to reference Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA. 1998;95:2498–502.CrossRef Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA. 1998;95:2498–502.CrossRef
11.
go back to reference Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, Mari A, Heine RJ, Diamant M. Pancreatic fat content and beta cell function in men with and without type 2 diabetes. Diabetes Care. 2007;11:2916–21.CrossRef Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, Mari A, Heine RJ, Diamant M. Pancreatic fat content and beta cell function in men with and without type 2 diabetes. Diabetes Care. 2007;11:2916–21.CrossRef
12.
go back to reference Lingvay I, Esser V, Legendre JL, Price AL, Werts KM, Adams-Huet B, Zhang S, Unger RH, Szczepaniak LS. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab. 2009;94:4070–6.CrossRef Lingvay I, Esser V, Legendre JL, Price AL, Werts KM, Adams-Huet B, Zhang S, Unger RH, Szczepaniak LS. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab. 2009;94:4070–6.CrossRef
13.
go back to reference Longo R, Pollescello P, Ricci C, Massutti F, Kvam BJ, Bercich L, Croce LS, Grigo-lato P, Paoletti S, De Bernard B. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5:281–5.CrossRef Longo R, Pollescello P, Ricci C, Massutti F, Kvam BJ, Bercich L, Croce LS, Grigo-lato P, Paoletti S, De Bernard B. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5:281–5.CrossRef
14.
go back to reference Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs JJ, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8.CrossRef Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs JJ, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8.CrossRef
15.
go back to reference Dixon W. Simple proton spectroscopic imaging. Radiology. 1984;153:189–94.CrossRef Dixon W. Simple proton spectroscopic imaging. Radiology. 1984;153:189–94.CrossRef
16.
go back to reference Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323–35.CrossRef Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323–35.CrossRef
17.
go back to reference Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes. 1993;42:1663–72.CrossRef Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes. 1993;42:1663–72.CrossRef
18.
go back to reference Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.CrossRef Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.CrossRef
19.
go back to reference Freitas P, Santos AC, Carvalho D. Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom. 2010;13:197–203.CrossRef Freitas P, Santos AC, Carvalho D. Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom. 2010;13:197–203.CrossRef
20.
go back to reference Ajluni N, Meral R, Neidert AH, et al. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol. 2017;86:698–707.CrossRef Ajluni N, Meral R, Neidert AH, et al. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol. 2017;86:698–707.CrossRef
21.
go back to reference Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;36:1047–55.CrossRef Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;36:1047–55.CrossRef
22.
go back to reference Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalization of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–14.CrossRef Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalization of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–14.CrossRef
23.
go back to reference Virtue S, Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol. 2008;6:e237.CrossRef Virtue S, Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol. 2008;6:e237.CrossRef
24.
go back to reference Scott RA, Fall T, Pasko D, Baker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, Ferranini E, Forouhi NG, Franks PW, Gavrila D, Giedraits V, Grioni S, Groop LC, Kaaks R, Key TJ, Kuhn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Rolandson O, Roswall N, Sacerdote C, Sala N, Sánchez MJ, Schulze MB, Siddig A, Slimani N, Sluijs I, Spiikerman AMW, Tjonneland A, Tumino R, van der A DL, Yaghootkar H, The RISC study group, The EPIC-InterAct consortium, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB, Langenberg C, Wareham NJ. Common genetic variants highlight the role of insulin resistant and body fat distribution in type 2 diabetes, independent of obesity. Diabetes. 2014;63:4378–87.CrossRef Scott RA, Fall T, Pasko D, Baker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, Ferranini E, Forouhi NG, Franks PW, Gavrila D, Giedraits V, Grioni S, Groop LC, Kaaks R, Key TJ, Kuhn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Rolandson O, Roswall N, Sacerdote C, Sala N, Sánchez MJ, Schulze MB, Siddig A, Slimani N, Sluijs I, Spiikerman AMW, Tjonneland A, Tumino R, van der A DL, Yaghootkar H, The RISC study group, The EPIC-InterAct consortium, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB, Langenberg C, Wareham NJ. Common genetic variants highlight the role of insulin resistant and body fat distribution in type 2 diabetes, independent of obesity. Diabetes. 2014;63:4378–87.CrossRef
25.
go back to reference Yaghootkar H, Scott RA, White CC, Zhang W, Speliotes E, Munroe PB, Ehret GB, Bis JCM, Fox CS, Walker M, Boreki IB, Zhang W, Knowles JW, Yerges-Armstrong L, Ohisson C, Perry JR, Chambers JC, Kooner JS, Franceschini N, Langenberg C, Hivert MF, Dastani Z, Richards JB, Semple RK, Frayling TM. Genetic evidence for a normal-weight “Metabolically Obese” phenotype linking insulin resistance, hypertension, coronary artery disease and type 2 diabetes. Diabetes. 2014;63:4369–77.CrossRef Yaghootkar H, Scott RA, White CC, Zhang W, Speliotes E, Munroe PB, Ehret GB, Bis JCM, Fox CS, Walker M, Boreki IB, Zhang W, Knowles JW, Yerges-Armstrong L, Ohisson C, Perry JR, Chambers JC, Kooner JS, Franceschini N, Langenberg C, Hivert MF, Dastani Z, Richards JB, Semple RK, Frayling TM. Genetic evidence for a normal-weight “Metabolically Obese” phenotype linking insulin resistance, hypertension, coronary artery disease and type 2 diabetes. Diabetes. 2014;63:4369–77.CrossRef
26.
go back to reference Stefan N, Schick F, Hari H. Causes, characteristics and consequences of Metabolically unhealthy normal weight in humans. Cell Metab. 2017;26:292–300.CrossRef Stefan N, Schick F, Hari H. Causes, characteristics and consequences of Metabolically unhealthy normal weight in humans. Cell Metab. 2017;26:292–300.CrossRef
27.
go back to reference Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, Gaulton KJ, Eicher JD, Sharp SJ, Luan J, Rolfe EDL, Stewart ID, Wheeler E, Willems SM, Adams C, Yaghootkar H, EPIC-InterAct Consortium, Cambridge FPLD1 Consortium, Forouhi NG, Khaw KT, Johnson AD, Semple RK, Frayling T, Perry JR, Dermitzakis E, McCarthy MI, Barroso I, Wareham NJ, Savage DB, Langenberg C, O’Rahilly S, Scott RA. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49:7–26.CrossRef Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, Gaulton KJ, Eicher JD, Sharp SJ, Luan J, Rolfe EDL, Stewart ID, Wheeler E, Willems SM, Adams C, Yaghootkar H, EPIC-InterAct Consortium, Cambridge FPLD1 Consortium, Forouhi NG, Khaw KT, Johnson AD, Semple RK, Frayling T, Perry JR, Dermitzakis E, McCarthy MI, Barroso I, Wareham NJ, Savage DB, Langenberg C, O’Rahilly S, Scott RA. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49:7–26.CrossRef
28.
go back to reference Akinci B, Onay H, Demir T, Savas-Erdeve Ş, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, Ozdemir NK, Atik T, Ozen S, Yurekli BS, Apaydin T, Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. Metab Clin Exp. 2017;72:109–19.CrossRef Akinci B, Onay H, Demir T, Savas-Erdeve Ş, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, Ozdemir NK, Atik T, Ozen S, Yurekli BS, Apaydin T, Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. Metab Clin Exp. 2017;72:109–19.CrossRef
29.
go back to reference Emdin CA, Khera AV, Natarajan P. Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes and coronary heart disease. JAMA. 2017;317:626–34.CrossRef Emdin CA, Khera AV, Natarajan P. Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes and coronary heart disease. JAMA. 2017;317:626–34.CrossRef
Metadata
Title
Pancreatic fat deposition is increased and related to beta-cell function in women with familial partial lipodystrophy
Authors
Amelio F. Godoy-Matos
Cynthia M. Valerio
Rodrigo O. Moreira
Denise P. Momesso
Leonardo K. Bittencourt
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2018
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-018-0375-9

Other articles of this Issue 1/2018

Diabetology & Metabolic Syndrome 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.